Compare Merck & Co., Inc. (MRK) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Symbotic Inc — how do they compare? Merck & Co., Inc. trades at $146.19 (market cap $351.28B), while Symbotic Inc trades at $42.55 (market cap $5.46B). The key difference: Merck & Co., Inc. is far larger — about 64.3× Symbotic Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Symbotic Inc for 23 Days on average.
| MRK | SYM | |
|---|---|---|
Market Cap | $351.28B | $5.46B |
Volume | 7,969,665 | 1,965,805 |
Sector | Health | Industrials |
52-Week High | $156.43 | $87.30 |
52-Week Low | $82.49 | $38.22 |
Typical Hold Time | 98 Days | 23 Days |
Enterprise Value | $398.04B | $3.72B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
SYM trades at $42.56, down 1.73% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $16.94 million in 2025, though revenue grew to $2.25 billion. Analysts maintain a consensus Buy rating with a $60.33 price target, citing a robust $22.5 billion backlog and positioning in warehouse automation.
The outlook hinges on execution of its large backlog and diversification beyond key customer Walmart. Near-term risks include recent earnings misses and high valuation multiples relative to current profitability. The stock offers growth potential if margin expansion and recurring revenue targets are met, but faces volatility from execution risks and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
